Navigation Links
Micromet Announces Changes in Management Team
Date:12/14/2007

1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the ri
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists ... can do to ensure that their practice will be a ... the basic supplies they use the most can make all ... many dentists have recently discovered that purchasing discount dental ... According to successful dentists across ...
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Dental Supplies Online is Key to Dental Success...Really! 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... Circle Biologics®, Inc. has announced a technological break-through in regenerative ... single device platform is the first of its kind to ... in one point-of-care device. , ... The APC patented design (which has ...
... 26 The Exergen temporal artery thermometer outsells ... Exergen TemporalScanner™, according to data compiled by leading market ... thermometers, including national brands and private label products, Nielsen ... on top. Exergen,s retail unit sales rose an average ...
Cached Medicine Technology:Circle Biologics® Introduces Innovation in Medical Devices 2Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2
(Date:7/25/2014)... Mahendra Trivedi and his wife Dahryn Trivedi ... Power’ on Saturday, July 26, 2014. People from all ... transforming event as they will get a chance to ... are left for the commencement of this rare event. ... Dahryn Trivedi (his wife) and Alice Branton will provide ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The ... the pot by revealing to the whole world, including even ... Satan, the devil, in his new article. , Yisrayl says ... and carried out by the Catholic Church. He says this ... Inspired Holy Scriptures and replacing it with titles such as ...
(Date:7/25/2014)... Recently, the largest herpes dating website ... that there had been a large increase in the number ... Living with a sexually transmitted disease can be difficult, but ... from all around the world who manage to go on ... many STDs including HSV, HPV, HIV, chlamydia, thrush, syphilis, hepatitis, ...
(Date:7/25/2014)... As the category creator and world leader in healthy chocolate, ... and improve individual lives worldwide through its exclusive and healthy ... successful Austin, Texas based "Xocai Activ Drink" author, is scheduled ... to promote the up and coming mxicorp.com/company/igc Eric Worre engagement ... been a leader in the Network Marketing Profession for over ...
(Date:7/24/2014)... Lawrence, KS (PRWEB) July 25, 2014 ... implant can be affected by the width of the ... to hold the implant. A variety of methods exist, ... and subsequent augmentation techniques. The ridge-split graft is highlighted ... , The Journal of Oral Implantology offers a ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3
... Pediatric cancer researchers at The Children,s Hospital of Philadelphia ... medulloblastoma, a type of brain tumor typically found in ... of this cancer, and holds intriguing clues to gene ... for future therapies. The most common cancerous brain ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) ... Thursday in the latest legal challenge to the constitutionality of ... -- that nearly all Americans must carry health insurance or ... in Virginia sided with that state,s attorney general, who contended ...
... (ACP) today made a guide to help inform consumers about ... Consumer Guide to Understanding Health System Reform is an ... a way that clearly explains what the law has changed, ... take effect. It was developed by ACP and AARP, ...
... Reporter , WEDNESDAY, Dec. 15 (HealthDay News) -- U.S. Food ... new look at data that may indicate potential safety problems ... ruled in 2009 that mercury used in so-called amalgam dental ... science is and if there are gaps," said the panel,s ...
... , THURSDAY, Dec. 16 (HealthDay News) -- A new U.S. ... largely through sodas. And the more caffeine they consumed, the ... Medical Center surveyed the parents of more than 200 children, ... pediatric clinic. The parents were asked about the types and ...
... but an important one: The number of babies who die ... percent on New Year,s Day. The suspected reason? Alcohol consumption ... Phillips of the University of California, San Diego, the study ... is published in the journal Addiction . The spike, ...
Cached Medicine News:Health News:CHOP experts collaborate in gene survey of childhood brain cancer; intriguing clues found 2Health News:Court Fight Over Health-Care Reform Shifts to Florida 2Health News:Court Fight Over Health-Care Reform Shifts to Florida 3Health News:Court Fight Over Health-Care Reform Shifts to Florida 4Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3Health News:SIDS spikes on New Year's Day 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: